Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 22:5:1210083.
doi: 10.3389/frph.2023.1210083. eCollection 2023.

Potential biomarkers to predict return to fertility after discontinuation of female contraceptives-looking to the future

Amanda Cordova-Gomez  1 , Andrew P Wong  2 , Lee B Sims  1 , Gustavo F Doncel  2 , Laneta J Dorflinger  3
Affiliations
Review

Potential biomarkers to predict return to fertility after discontinuation of female contraceptives-looking to the future

Amanda Cordova-Gomez et al. Front Reprod Health. .

Abstract

Nowadays there are multiple types of contraceptive methods, from reversible to permanent, for those choosing to delay pregnancy. Misconceptions about contraception and infertility are a key factor for discontinuation or the uptake of family planning methods. Regaining fertility (the ability to conceive) after contraceptive discontinuation is therefore pivotal. Technical studies to date have evaluated return to fertility by assessing pregnancy as an outcome, with variable results, or return to ovulation as a surrogate measure by assessing hormone levels (such as progesterone, LH, FSH) with or without transvaginal ultrasound. In general, relying on time to pregnancy as an indicator of return to fertility following contraceptive method discontinuation can be problematic due to variable factors independent of contraceptive effects on fertility, hormone clearance, and fertility recovery. Since the ability to conceive after contraceptive method discontinuation is a critical factor influencing product uptake, it is important to have robust biomarkers that easily and accurately predict the timing of fertility return following contraception and isolate that recovery from extrinsic and circumstantial factors. The main aim of this review is to summarize the current approaches, existing knowledge, and gaps in methods of evaluating return-to-fertility as well as to provide insights into the potential of new biomarkers to more accurately predict fertility restoration after contraceptive discontinuation. Biomarker candidates proposed in this document include those associated with folliculogenesis, cumulus cell expansion, follicular rupture and ovulation, and endometrial transport and receptivity which have been selected and scored on predefined criteria meant to evaluate their probable viability for advancement. The review also describes limitations, regulatory requirements, and a potential path to clinically testing these selected biomarkers. It is important to understand fertility restoration after contraceptive method discontinuation to provide users and health providers with accurate evidence-based information. Predictive biomarkers, if easy and low-cost, have the potential to enable robust evaluation of RTF, and provide potential users the information they desire when selecting a contraceptive method. This could lead to expanded uptake and continuation of modern contraception and inform the development of new contraceptive methods to widen user's family planning choices.

Keywords: biomarker; contraception; folliculogenesis; hormonal; ovulation; pregnancy; progesterone; return to fertility.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs (CCP), Knowledge for Health Project. Family planning: A Global Handbook for Providers (2018 update). Baltimore and Geneva: CCP and WHO; (2018).
    1. Al Dalaty A, Gualeni B, Coulman SA, Birchall JC. Models and methods to characterise levonorgestrel release from intradermally administered contraceptives. Drug Deliv Transl Res. (2022) 12(2):335–49. 10.1007/s13346-021-01091-5 - DOI - PMC - PubMed
    1. Nelson AL. The new low-dose transdermal contraceptive system (Twirla(®)): results from preclinical and phase iii trials. Ther Deliv. (2021) 12(7):501–14. 10.4155/tde-2021-0001 - DOI - PubMed
    1. Gilbert AL, Hoffman BL. Contraceptive technology: present and future. Obstet Gynecol Clin North Am. (2021) 48(4):723–35. 10.1016/j.ogc.2021.07.001 - DOI - PubMed
    1. United Nations Department of Economic and Social Affairs PD. World family planning 2020 highlights: accelerating action to ensure universal access to family planning (st/esa/ser.A/450). New York: United Nations; (2020).

LinkOut - more resources